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acceptable incidence of side effects was recorded. 
Furthermore, it was possible to avoid colostomy in a 
significant proportion of patients. 
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Purpose or Objective: To define the Maximum Tolerated 
Dose (MTD) of Middle Half Body (MHB) Radiotherapy (RT) 
delivered with a conformal 3D technique and twice daily 
fractionation in prostate cancer (PC) multiple bone 
metastases. 
 
Material and Methods: A phase I trial was designed with two 
level of dose: 13 Gy (3.25Gy per fraction) and 15 Gy (3.75 Gy 
per fraction). Eligibility criteria were: histological confirmed 
PC, symptomatic and or impending for fracture multiple bone 
metastases, ECOG performance status 0-4, expected survival 
>3 months, and adequate bone marrow function. 
Radiotherapy was delivered using a 3D conformal technique 
twice daily in 2 sequential days, with at least 8 hours interval 
between fractions. Cohort of 6-12 patients were recruited in 
order to define the MTD (any acute toxicity > grade 3 of 
RTOG scale). Pain and quality of life were recorded using 
analogue-visual scales (VAS and CLAS). Clinical target volume 
was defined as pelvic bones, involved femurs + lumbar spine. 
Planning target volume was defined as the CTV + 1 cm. 
 
Results: From June 2010 to November 2014, 22 patients 
(median age 73 years; range 58-86) were enrolled. In Figure 1 




At diagnosis, all patients (100%) reported pain. Clinical pain 
remission (complete or partial) was observed in 95% of 
patients. Six patients (27.3%) had a complete symptoms 
resolution and 15 (68.2%) had a partial symptom control. Pain 
worsening after radiation treatment was recorded only in 1 
patient. On the basis of analogue-visual scales a significant 
decrease of pain was recorded (mean VAS pre RT versus post 
RT: 4.6 versus 3,0; p=0.034; mean pain score pre RT versus 
post RT: 3.1 versus 1,9; p=0.069; mean drug score pre RT 
versus post RT: 3.9 versus 2,5; p=0.088). Skin and 
gastrointestinal acute toxicities were only grade 1-2. With a 
median follow up of 6 months (range 1-26) no late toxicity 
was recorded. 
 
Conclusion: An accelerated MHB RT treatment with twice 
daily fraction on bone metastases from PC was well tolerated 
up to 15 Gy. A phase II study is ongoing to confirm efficacy on 
pain control and quality of life. 
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Purpose or Objective: To evaluate the factors associated 
with treatment response (relieve of SVCS) and overall 
survival. 
 
Material and Methods: Thirty one patients with SVCS 
between 2012-2015 were analyzed. The end points were: 
overall survival and SVCS resolution. SVCS resolution was 
determined as the absence of symptoms related to the 
compression of superior vena cava. The variables tested 
were: sex (male vs female), age (<50 years vs > 50 years), 
primary site (lung vs others), KPS (<70 vs >/= 70), previous 
palliative RT (no vs yes), BED Gy10 dose (<25 vs > 25), more 
than 1 year of the initial diagnosis (no vs yes), tumor size 
(<10 cm vs >/= 10 cm), and number of previous 
chemotherapy (CT) lines (0 or 1 vs 2 or more), presence of: 
bone mets (no vs yes), central nervous system (SNC) mets (no 
vs yes), lung mets (no vs yes), liver mets (no vs yes), lymph 
node mets (no vs yes) and SVCS resolution (no vs yes). 
 
Results: The mean follow-up time of the patients alive was 
376 days (median 241 days). The 6-months and 1-year OS 
survival were 31.5 % and 18 %, respectively. Factors 
influencing positively the survival in univariate analysis were: 
KPS >/= 70 (p=0.001), 0 or 1 previous CT lines (p=0.012), 
diagnosis <1y (p=0.007), no bone mets (p=0.010), no lung 
mets (p=0.011), no liver mets (p=0.031) and SVCS resolution 
(p<0.001). In multivariate analysis only SVCS resolution 
(p=0.005) remained significant and no lung metastasis was 
marginally related (p=0.060). The overall SVCS resolution 
rate was 84% (12/25 cases). Nineteen patient were treated 
with radiotherapy (RT), four patient with chemotherapy and 
2 patients with RT + CT. Six cases receive no treatment (3 
because of extremely low KPS and 3 because of the risks of 
re-irradiation) and were excluded from the efficacy and 
multifactorial analysis. None of the variables tested 
influenced the treatment response rate. 
 
Conclusion: Treatment response rate was more than 80 % 
and it was the strongest factor associated with overall 
survival. This fact encourages the indication of treatment 
even in patients with low performance status or previous 
cervico-thoracic radiotherapy, after a risk-benefit analysis. 
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Purpose or Objective: The aim of this analysis was to 
determine the risk of vertebral compression fracture (VCF) 
following spine radiotherapy (RT) specific to colorectal 
cancer (CRC) spinal metastases, and to determine clinical 
predictors 
 
Material and Methods: We retrospectively reviewed 267 
spinal segments (176 metastatic and 91 non-metastatic 
vertebras) in 66 patients, which were irradiated for pain 
palliation between 2007 and 2014. The primary endpoint was 
development of a VCF following RT, either a de novo VCF or 
